EGFR and glioblastoma: A landmark preclinical study demonstrated that the dual inhibition of the EGFR/AKT and mevalonate pathways synergistically enhances the antitumor activity of TMZ in glioblastomas by inducing metabolic reprogramming and exposing vulnerabilities in energy metabolism.